Charles W. Qualls

Amgen (United States)

Papers

1

Total Citations

15

H-Index

1

About

Charles W. Qualls is a pioneering figure in the field of high-throughput drug screening, with a focused expertise in single-cell analysis and automated pharmacological systems. His most notable contribution, the 2013 paper "High-Throughput Secondary Screening at the Single-Cell Level," introduced a groundbreaking automated platform that integrates semiautomated preparation, high-speed sample collection, and real-time analytical tools to assess multiple functional responses from individual cells. This work, which has garnered 15 citations, enables instantaneous evaluation of compound dilutions in 384-well formats, significantly accelerating the drug discovery pipeline. Qualls’ innovation addresses a critical bottleneck in secondary screening by providing unprecedented resolution and efficiency, allowing researchers to capture heterogeneous cellular responses often missed by bulk assays. His approach has been recognized for its potential to transform preclinical toxicology and therapeutic development, offering a scalable solution for identifying lead compounds with greater precision. Through this achievement, Qualls has established himself as a key contributor to the advancement of single-cell technologies, bridging the gap between high-throughput automation and functional cellular analysis.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
High-Throughput Secondary Screening at the Single-Cell Level
15 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Amgen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago